Dragon’s Curse: U.S. Biotech and Chinese Investment Dilemma
Chinese investors are filling the funding gap in U.S. biotech, but the risks of their capital extend beyond geopolitics. One medtech company’s struggle reveals the hidden costs.
Browsing Category